| Primary |
| Product Used For Unknown Indication |
26.7% |
| Foetal Exposure During Pregnancy |
9.0% |
| Liver Disorder |
8.6% |
| Biliary Cirrhosis Primary |
7.8% |
| Hepatitis C |
7.1% |
| Cholangitis Sclerosing |
5.5% |
| Cholelithiasis |
5.1% |
| Cholestasis |
4.3% |
| Bile Duct Stone |
3.1% |
| Crohn's Disease |
2.7% |
| Asthma |
2.4% |
| Cerebral Infarction |
2.4% |
| Hepatic Function Abnormal |
2.4% |
| Hyperthyroidism |
2.4% |
| Transplant |
2.4% |
| Hypertension |
2.0% |
| Ascites |
1.6% |
| Autoimmune Hepatitis |
1.6% |
| Chronic Hepatitis |
1.6% |
| Drug Use For Unknown Indication |
1.6% |
|
| Interstitial Lung Disease |
16.4% |
| Liver Transplant |
9.8% |
| Jaundice |
6.6% |
| Bile Duct Stone |
4.9% |
| Disease Progression |
4.9% |
| Lymphocyte Stimulation Test Positive |
4.9% |
| Maternal Drugs Affecting Foetus |
4.9% |
| Pruritus |
4.9% |
| Renal Disorder |
4.9% |
| Urticaria |
4.9% |
| Anaemia |
3.3% |
| Biliary Tract Infection |
3.3% |
| Dyspnoea |
3.3% |
| Hepatic Function Abnormal |
3.3% |
| Hepatic Neoplasm Malignant |
3.3% |
| Liver Disorder |
3.3% |
| Liver Function Test Abnormal |
3.3% |
| Malignant Neoplasm Progression |
3.3% |
| Musculoskeletal Disorder |
3.3% |
| Pruritus Generalised |
3.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
40.4% |
| Product Used For Unknown Indication |
10.5% |
| Prophylaxis |
8.4% |
| Hepatitis C |
6.0% |
| Foetal Exposure During Pregnancy |
3.3% |
| Insomnia |
3.3% |
| Hypertension |
3.0% |
| Ill-defined Disorder |
3.0% |
| Autoimmune Hepatitis |
2.7% |
| Drug Exposure During Pregnancy |
2.4% |
| Hepato-lenticular Degeneration |
2.4% |
| Pruritus |
2.1% |
| Asthma |
1.8% |
| Cholestasis Of Pregnancy |
1.8% |
| Renal Transplant |
1.8% |
| Biliary Cirrhosis Primary |
1.5% |
| Crohn's Disease |
1.5% |
| Liver Transplant |
1.5% |
| Cholangitis Sclerosing |
1.2% |
| Cholelithiasis |
1.2% |
|
| Jaundice |
41.3% |
| Premature Baby |
12.7% |
| Aplastic Anaemia |
3.2% |
| Drug Exposure During Pregnancy |
3.2% |
| Dysmorphism |
3.2% |
| Liver Function Test Abnormal |
3.2% |
| Maternal Exposure During Pregnancy |
3.2% |
| Rash |
3.2% |
| Retinal Haemorrhage |
3.2% |
| Schizophrenia |
3.2% |
| Toxic Epidermal Necrolysis |
3.2% |
| Tubulointerstitial Nephritis |
3.2% |
| Withdrawal Syndrome |
3.2% |
| Abdominal Pain |
1.6% |
| Autoimmune Hepatitis |
1.6% |
| Bile Duct Stone |
1.6% |
| Blood Bilirubin Increased |
1.6% |
| Brain Malformation |
1.6% |
| Colonic Haematoma |
1.6% |
| Complications Of Transplanted Kidney |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
39.5% |
| Prophylaxis |
10.6% |
| Drug Use For Unknown Indication |
9.8% |
| Infection Prophylaxis |
5.0% |
| Prophylaxis Against Graft Versus Host Disease |
4.0% |
| Bone Marrow Conditioning Regimen |
3.6% |
| Hypertension |
3.1% |
| Premedication |
2.9% |
| Crohn's Disease |
2.7% |
| Antifungal Prophylaxis |
2.4% |
| Acute Myeloid Leukaemia |
2.1% |
| Rheumatoid Arthritis |
2.1% |
| Hepatitis C |
2.0% |
| Pain |
1.8% |
| Insomnia |
1.7% |
| Constipation |
1.5% |
| Antiviral Prophylaxis |
1.4% |
| Diabetes Mellitus |
1.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.3% |
| Hepatic Neoplasm Malignant |
1.2% |
|
| Vomiting |
16.1% |
| White Blood Cell Count Decreased |
9.4% |
| Pyrexia |
6.5% |
| Sepsis |
5.4% |
| Thrombocytopenia |
5.4% |
| Weight Increased |
5.4% |
| Weight Decreased |
5.2% |
| Death |
4.9% |
| Pneumonia |
4.5% |
| Venoocclusive Liver Disease |
4.3% |
| Diarrhoea |
3.8% |
| Venoocclusive Disease |
3.8% |
| Tremor |
3.4% |
| Hepatic Failure |
3.3% |
| Platelet Count Decreased |
3.3% |
| Renal Failure Acute |
3.3% |
| Septic Shock |
3.3% |
| Jaundice |
2.9% |
| Nausea |
2.9% |
| Rash |
2.9% |
|
| Interacting |
| Drug Use For Unknown Indication |
26.7% |
| Anxiety |
13.3% |
| Bipolar I Disorder |
13.3% |
| Depression |
13.3% |
| Liver Disorder |
13.3% |
| Smoking Cessation Therapy |
13.3% |
| Rheumatoid Arthritis |
6.7% |
|
| Depression |
33.3% |
| Drug Interaction |
33.3% |
| Transaminases Increased |
33.3% |
|
